Denosumab (Prolia®) is a human monoclonal antibody that binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Prolia prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts and their precursors. Prevention of the RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby decreasing bone resorption and increasing bone mass and strength in both cortical and trabecular bone. BioSim™ Denosumab ELISA kit has been developed for specific quantification of Denosumab concentration in human serum or plasma with high sensitivity and reproducibility.
产品特点
• Easy, convenient, sensitive and time-saving method to measure the level of Denosumab in human serum and plasma.
• Detection Range: 3 - 300 ng/ml
• Sensitivity: 3 ng/ml
• Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100)
• Recovery rate: 85 – 115% with normal human serum samples with known concentrations
• Cross Reactivity: There is no cross reaction with native serum immunoglobulins and tested monoclonal antibodies such as infliximab (Remicade®), adalimumab (Humira®), trastuzumab (Herceptin®) and bevacizumab (Avastin®)